Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Björkholm M[au]:

Acute myeloid leukaemia. Khwaja A et al. Nat Rev Dis Primers. (2016)

Human 15-lipoxygenase-1 is a regulator of dendritic-cell spreading and podosome formation. Han H et al. FASEB J. (2017)

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. Bower H et al. J Clin Oncol. (2016)

Search results

Items: 1 to 50 of 503

1.

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.

Lagerlöf I, Holte H, Glimelius I, Björkholm M, Enblad G, Erlanson M, Fluge Ø, Fohlin H, Fosså A, Goldkuhl C, Gustavsson A, Johansson AS, Linderoth J, Nome O, Palma M, Åkesson L, Østenstad B, Raud C, Glimelius B, Molin D.

Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16232. [Epub ahead of print]

PMID:
31612478
2.

An intronic deletion in megakaryoblastic leukemia 1 is associated with hyperproliferation of B cells in triplets with Hodgkin lymphoma.

Record J, Sendel A, Kritikou JS, Kuznetsov NV, Brauner H, He M, Nagy N, Oliveira MMS, Griseti E, Haase CB, Dahlström J, Boddul S, Wermeling F, Thrasher AJ, Liu C, Andersson J, Claesson HE, Winqvist O, Burns SO, Björkholm M, Westerberg LS.

Haematologica. 2019 Oct 3. pii: haematol.2019.216317. doi: 10.3324/haematol.2019.216317. [Epub ahead of print]

3.

Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.

Schain F, Vago E, Song C, He J, Liwing J, Löfgren C, Björkholm M.

Eur J Haematol. 2019 Dec;103(6):614-619. doi: 10.1111/ejh.13330. Epub 2019 Oct 4.

PMID:
31536656
4.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
5.

Loss in life expectancy and gain in life years as measures of cancer impact.

Rutherford MJ, Andersson TM, Björkholm M, Lambert PC.

Cancer Epidemiol. 2019 Jun;60:168-173. doi: 10.1016/j.canep.2019.04.005. Epub 2019 May 1. Review.

PMID:
31054465
6.

Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and the United States.

Björkholm M, Edgren G, Dickman PW.

Blood. 2019 Jul 25;134(4):407-410. doi: 10.1182/blood.2019001168. Epub 2019 Apr 25. No abstract available.

PMID:
31023701
7.

Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Sverrisdóttir IS, Lund SH, Turesson I, Björkholm M, Goldin LR, Landgren O, Kristinsson SY.

Br J Haematol. 2019 Jul;186(1):37-44. doi: 10.1111/bjh.15883. Epub 2019 Mar 24.

PMID:
30906990
8.

The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma.

Ma R, Liu C, Lu M, Yuan X, Cheng G, Kong F, Lu J, Strååt K, Björkholm M, Ma L, Xu D.

Urol Oncol. 2019 May;37(5):301.e1-301.e10. doi: 10.1016/j.urolonc.2019.01.014. Epub 2019 Feb 7.

PMID:
30738744
9.

ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells.

Wu Y, Li X, Yu J, Björkholm M, Xu D.

Cell Death Dis. 2019 Jan 28;10(2):76. doi: 10.1038/s41419-019-1357-z.

10.

Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients.

Weibull CE, Björkholm M, Glimelius I, Lambert PC, Andersson TML, Smedby KE, Dickman PW, Eloranta S.

Int J Cancer. 2019 Sep 1;145(5):1200-1208. doi: 10.1002/ijc.32142. Epub 2019 Feb 5.

PMID:
30666628
11.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms.

Hultcrantz M, Björkholm M, Landgren O, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Aug 21;169(4):268. doi: 10.7326/L18-0245. No abstract available.

PMID:
30128518
12.

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.

Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I.

J Clin Oncol. 2018 Sep 10;36(26):2718-2725. doi: 10.1200/JCO.2018.78.3514. Epub 2018 Jul 25.

PMID:
30044694
13.

Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.

Yu J, Yuan X, Sjöholm L, Liu T, Kong F, Ekström TJ, Björkholm M, Xu D.

Cancer Lett. 2018 Oct 10;434:33-41. doi: 10.1016/j.canlet.2018.07.013. Epub 2018 Jul 11.

PMID:
30017965
14.

Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.

Zhang X, Li B, Yu J, Dahlström J, Tran AN, Björkholm M, Xu D.

Ann Hematol. 2018 Jul;97(7):1299. doi: 10.1007/s00277-018-3340-7.

15.

Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden.

Björkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW.

Eur J Haematol. 2018 Jul;101(1):106-114. doi: 10.1111/ejh.13090. Epub 2018 May 23.

PMID:
29727497
16.

Prevalence of Celiac Disease in Patients With Iron Deficiency Anemia-A Systematic Review With Meta-analysis.

Mahadev S, Laszkowska M, Sundström J, Björkholm M, Lebwohl B, Green PHR, Ludvigsson JF.

Gastroenterology. 2018 Aug;155(2):374-382.e1. doi: 10.1053/j.gastro.2018.04.016. Epub 2018 Apr 22. Review.

PMID:
29689265
17.

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O.

Eur J Haematol. 2018 Apr 20. doi: 10.1111/ejh.13083. [Epub ahead of print] Review.

18.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22. No abstract available.

19.

Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.

Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Björkholm M, Kristinsson SY, Hultcrantz M.

Leukemia. 2018 Oct;32(10):2203-2210. doi: 10.1038/s41375-018-0027-y. Epub 2018 Jan 30.

PMID:
29535425
20.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.

PMID:
29335713
21.

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, Jethava YS, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.

22.

MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.

Zhang X, Li B, Yu J, Dahlström J, Tran AN, Björkholm M, Xu D.

Ann Hematol. 2018 Jan;97(1):63-72. doi: 10.1007/s00277-017-3158-8. Epub 2017 Oct 27. Erratum in: Ann Hematol. 2018 Apr 25;:. Björkhom M [corrected to Björkholm M].

23.

Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β-Catenin Target Genes.

Liang X, Yuan X, Yu J, Wu Y, Li K, Sun C, Li S, Shen L, Kong F, Jia J, Björkholm M, Xu D.

EBioMedicine. 2017 Jul;21:104-116. doi: 10.1016/j.ebiom.2017.06.007. Epub 2017 Jun 8.

24.

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. No abstract available.

25.

The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.

Yuan X, Cheng G, Yu J, Zheng S, Sun C, Sun Q, Li K, Lin Z, Liu T, Li P, Xu Y, Kong F, Bjorkholm M, Xu D.

Oncotarget. 2017 Apr 4;8(14):23120-23129. doi: 10.18632/oncotarget.15498.

26.

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.

Madapura HS, Nagy N, Ujvari D, Kallas T, Kröhnke MCL, Amu S, Björkholm M, Stenke L, Mandal PK, McMurray JS, Keszei M, Westerberg LS, Cheng H, Xue F, Klein G, Klein E, Salamon D.

Oncogene. 2017 Aug 10;36(32):4619-4628. doi: 10.1038/onc.2017.85. Epub 2017 Apr 3.

PMID:
28368400
27.

Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].

Garcia C, Rosén A, Kimby E, Aguilar-Santelises M, Jondal M, Björkholm M, Holm G, Mellstedt H.

Leuk Res. 2017 Jun;57:127. doi: 10.1016/j.leukres.2017.01.029. Epub 2017 Mar 15. No abstract available.

PMID:
28314441
28.

Assessing nursing students' knowledge and skills in performing venepuncture and inserting peripheral venous catheters.

Ahlin C, Klang-Söderkvist B, Johansson E, Björkholm M, Löfmark A.

Nurse Educ Pract. 2017 Mar;23:8-14. doi: 10.1016/j.nepr.2017.01.003. Epub 2017 Jan 27.

PMID:
28171853
29.

Reply to D. Pulte et al.

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM.

J Clin Oncol. 2017 Feb 20;35(6):696-697. doi: 10.1200/JCO.2016.70.9279. Epub 2016 Nov 28. No abstract available.

PMID:
27893321
30.

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Pauly F, Fjordén K, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M, Isinger-Ekstrand A, Borrebaeck CA, Jerkeman M, Wingren C.

Blood Cancer J. 2016 Nov 18;6(11):e501. doi: 10.1038/bcj.2016.113. No abstract available.

31.

Human 15-lipoxygenase-1 is a regulator of dendritic-cell spreading and podosome formation.

Han H, Liang X, Ekberg M, Kritikou JS, Brunnström Å, Pelcman B, Matl M, Miao X, Andersson M, Yuan X, Schain F, Parvin S, Melin E, Sjöberg J, Xu D, Westerberg LS, Björkholm M, Claesson HE.

FASEB J. 2017 Feb;31(2):491-504. doi: 10.1096/fj.201600679RR. Epub 2016 Oct 17.

PMID:
27825104
32.

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Björkholm M, Kristinsson SY.

Ann Hematol. 2017 Feb;96(2):261-269. doi: 10.1007/s00277-016-2859-8. Epub 2016 Nov 2.

33.

Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.

Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, Ullén A, Zhivotovsky B, Björkholm M, Panaretakis T.

Blood. 2016 Dec 8;128(23):2655-2665. Epub 2016 Oct 14.

PMID:
27742710
34.

TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.

Dahlström J, Liu T, Yuan X, Saft L, Ghaderi M, Wei YB, Lavebratt C, Li P, Zheng C, Björkholm M, Xu D.

Ann Hematol. 2016 Oct;95(11):1825-32. doi: 10.1007/s00277-016-2787-7. Epub 2016 Aug 25.

35.

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM.

J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.

PMID:
27325849
36.

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group.

Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14.

PMID:
27295519
37.

Acute myeloid leukaemia.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

PMID:
27159408
38.

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2016 Jul;30(7):1562-7. doi: 10.1038/leu.2016.59. Epub 2016 Mar 8.

PMID:
27080811
39.

The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.

Yuan X, Liu C, Wang K, Liu L, Liu T, Ge N, Kong F, Yang L, Björkholm M, Fan Y, Zhao S, Xu D.

Oncotarget. 2016 May 3;7(18):25826-35. doi: 10.18632/oncotarget.8404.

40.

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M.

J Clin Oncol. 2016 May 20;34(15):1829-30. doi: 10.1200/JCO.2015.65.0879. Epub 2016 Mar 21. No abstract available.

41.

Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.

Kjellander C, Björkholm M, Källman O, Giske CG, Weibull CE, Löve TJ, Landgren O, Kristinsson SY.

Ann Hematol. 2016 May;95(6):871-9. doi: 10.1007/s00277-016-2643-9. Epub 2016 Mar 15.

PMID:
26976017
42.

The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.

Yuan X, Meng Y, Li P, Ge N, Kong F, Yang L, Björkholm M, Zhao S, Xu D.

Oncotarget. 2016 May 31;7(22):31972-9. doi: 10.18632/oncotarget.7777.

43.

Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life.

Bower H, Andersson TM, Björkholm M, Dickman PW, Lambert PC, Derolf ÅR.

Blood Cancer J. 2016 Feb 5;6:e390. doi: 10.1038/bcj.2016.3.

44.

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, Olsson-Strömberg U, Richter J, Själander A.

Eur J Haematol. 2016 Oct;97(4):387-92. doi: 10.1111/ejh.12743. Epub 2016 Feb 26.

PMID:
26833713
45.

Blood donation and risk of polycythemia vera.

Edgren G, Nyrén O, Hultcrantz M, Nielsen KR, Pedersen OB, Björkholm M, Rostgaard K, Hjalgrim H.

Transfusion. 2016 Jun;56(6 Pt 2):1622-7. doi: 10.1111/trf.13499. Epub 2016 Feb 2.

PMID:
26830533
46.

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Wahlin A, Mailankody S, Blimark C, Hultcrantz M, Porwit A, Landgren O, Kristinsson SY.

Haematologica. 2016 Apr;101(4):e145-8. doi: 10.3324/haematol.2015.134049. Epub 2015 Dec 17. No abstract available.

47.

Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.

Weibull CE, Eloranta S, Smedby KE, Björkholm M, Kristinsson SY, Johansson AL, Dickman PW, Glimelius I.

J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14.

PMID:
26668344
48.

Brain tumors in patients with myotonic dystrophy: a population-based study.

Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Landgren O, Greene MH.

Eur J Neurol. 2016 Mar;23(3):542-7. doi: 10.1111/ene.12886. Epub 2015 Oct 28.

49.

Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.

Ci X, Li B, Ma X, Kong F, Zheng C, Björkholm M, Jia J, Xu D.

Oncotarget. 2015 Nov 10;6(35):38079-92. doi: 10.18632/oncotarget.5752.

50.

Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics.

Glimelius I, Ekberg S, Jerkeman M, Chang ET, Björkholm M, Andersson TM, Smedby KE, Eloranta S.

Am J Hematol. 2015 Dec;90(12):1128-34. doi: 10.1002/ajh.24184. Epub 2015 Oct 6.

Supplemental Content

Loading ...
Support Center